Novel RET Inhibitor BOS172738 in RET-Altered Cancers Including RET Fusion–Positive NSCLC and RET Mutation–Positive Medullary Thyroid Cancer

June 4-8, 2021; Online at https://conferences.asco.org/am
BOS127238, a novel, highly selective RET inhibitor, was associated with a manageable safety profile and preliminary efficacy in a phase I study in RET-altered solid tumors.
Format: Microsoft PowerPoint (.ppt)
File Size: 444 KB
Released: June 8, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Related Content

Expert faculty share patient case examples from clinical practice that highlight the importance of biomarker testing for NSCLC, from Clinical Care Options (CCO)

Charles W. Flexner, MD Released: September 23, 2022

Phase III CodeBreaK 200 study of sotorasib vs docetaxel in previously treated KRAS G12C-mutated advanced non-small-cell lung cancer, presented at ESMO 2022 as reported by Clinical Care Options (CCO)

Released: September 22, 2022

Downloadable slideset on established and emerging biomarkers critical to optimal use of targeted therapy and immunotherapy in patients with NSCLC

Zofia Piotrowska, MD, MHS Karen L. Reckamp, MD, MS Released: September 21, 2022

Downloadable slideset on optimal management of EGFR+ NSCLC, including expert insights on promising investigational agents and combination therapy, from Clinical Care Options (CCO)

Edward B. Garon, MD, MS Helena A. Yu, MD Released: September 21, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings